Academic literature on the topic 'Pharmaceutical services New Zealand'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Pharmaceutical services New Zealand.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Journal articles on the topic "Pharmaceutical services New Zealand"
1
Hatah, Ernieda, Rhiannon Braund, Stephen Duffull, and June Tordoff. "General practitioners’ perceptions of pharmacists’ new services in New Zealand." International Journal of Clinical Pharmacy 34, no. 2 (February 23, 2012): 364–73. http://dx.doi.org/10.1007/s11096-012-9617-3.
Full text
2
Gauld, Robin. "Health Care Rationing Policy in New Zealand: Development and Lessons." Social Policy and Society 3, no. 3 (June 22, 2004): 235–42. http://dx.doi.org/10.1017/s1474746404001745.
Full textAbstract:
This article discusses New Zealand's experiences with health care rationing policy. It reviews attempts to define ‘core services’, the development of prioritisation techniques for service access and funding, new technology assessment, and the management of subsidised pharmaceuticals. The New Zealand experience offers various lessons: that rationing policy development is, by nature, a ‘messy’ process; that central coordination of rationing policy is crucial unless differentiation in regional initiatives and service access are desired; and that through ongoing highlighting of the need for it, rationing policy development is likely to become an accepted reality.
3
Cutting, Rachel B., Angela C. Webster, Nicholas B. Cross, Heather Dunckley, Ben Beaglehole, Ian Dittmer, John Irvine, et al. "AcceSS and Equity in Transplantation (ASSET) New Zealand: Protocol for population-wide data linkage platform to investigate equity in access to kidney failure health services in New Zealand." PLOS ONE 17, no. 8 (August 25, 2022): e0273371. http://dx.doi.org/10.1371/journal.pone.0273371.
Full textAbstract:
Background Kidney transplantation is considered the ideal treatment for most people with kidney failure, conferring both survival and quality of life advantages, and is more cost effective than dialysis. Yet, current health systems may serve some people better than others, creating inequities in access to kidney failure treatments and health outcomes. AcceSS and Equity in Transplantation (ASSET) investigators aim to create a linked data platform to facilitate research enquiry into equity of health service delivery for people with kidney failure in New Zealand. Methods The New Zealand Ministry of Health will use patients’ National Health Index (NHI) numbers to deterministically link individual records held in existing registry and administrative health databases in New Zealand to create the data platform. The initial data linkage will include a study population of incident patients captured in the Australia and New Zealand Dialysis and Transplant Registry (ANZDATA), New Zealand Blood Service Database and the Australia and New Zealand Living Kidney Donor Registry (ANZLKD) from 2006 to 2019 and their linked health data. Health data sources will include National Non-Admitted Patient Collection Data, National Minimum Dataset, Cancer Registry, Programme for the Integration of Mental Health Data (PRIMHD), Pharmaceutical Claims Database and Mortality Collection Database. Initial exemplar studies include 1) kidney waitlist dynamics and pathway to transplantation; 2) impact of mental illness on accessing kidney waitlist and transplantation; 3) health service use of living donors following donation. Conclusion The AcceSS and Equity in Transplantation (ASSET) linked data platform will provide opportunity for population-based health services research to examine equity in health care delivery and health outcomes in New Zealand. It also offers potential to inform future service planning by identifying where improvements can be made in the current health system to promote equity in access to health services for those in New Zealand.
4
Hatah, Ernieda, June Tordoff, Stephen B. Duffull, Claire Cameron, and Rhiannon Braund. "Retrospective examination of selected outcomes of Medicines Use Review (MUR) services in New Zealand." International Journal of Clinical Pharmacy 36, no. 3 (March 15, 2014): 503–12. http://dx.doi.org/10.1007/s11096-014-9913-1.
Full text
5
Martins, Jo M. "Health Systems in Australia and Four Other Countries: choices and challenges." Asia Pacific Journal of Health Management 11, no. 3 (October 1, 2016): 45–57. http://dx.doi.org/10.24083/apjhm.v11i3.155.
Full textAbstract:
The purpose of health systems is the pursuit of healthy lives. The performance of the Australian health system over the last decade is compared with the United Kingdom and its three other offshoots: the United States, Canada and New Zealand. In the first instance, system performance is assessed in terms of threats to healthy lives from risk factors and changes that have taken place during the decade. In view of the emphasis of the five systems on the return to health after trauma and illness, and the human-resource intensity of health services, an appraisal is made of changes in the number of the major health professionals in relation to the growing populations. Then related changes in hospital, medical practitioner and dentist services are assessed. Changes in pharmaceutical drug prescriptions in Australian are also examined. The levels of national expenditures arising from the provision health services are then considered in the context of the costs of administration of the varied organisational modes, use of expensive medical technologies, pharmaceutical drug consumption and remuneration of health professionals. Finally, health outcomes in Australia and the other four countries are assessed in accordance with their human development level, life expectancy, potential years of life lost from different causes, as well as healthy life expectancies. Further, gaps in health and life expectancy of Indigenous people in the United States, Canada, New Zealand and Australia are reviewed, as well as health and survival inequalities among people in different social strata in each country.
Abbreviations: GDP – Gross Domestic Product; HDI – Human Development Index.
6
Abdul Aziz, Yasmin, Susan J. Heydon, Stephen B. Duffull, and Carlo A. Marra. "Are professional pharmacy services being offered for free in pharmacies? A feasibility study exploring the use of a time motion study in New Zealand." Pharmacy Practice 19, no. 2 (July 31, 2021): 2422. http://dx.doi.org/10.18549/pharmpract.2021.3.2422.
Full textAbstract:
Background: Pharmacists report to be providing patient-focused clinical services for which they receive no remuneration. Limited literature exists about unfunded services leading to difficulties in ascertaining an appropriate study design for such research.
Objective: This study aims to assess the appropriateness of a proposed study design before launching a nationwide study to investigate the provision of unfunded patient care services.
Methods: A multi-methods approach was utilised consisting of (1) continuous time motion study in community pharmacies (2) semi structured patient interviews (3) patient follow up (4) semi structured interviews with pharmacy owners/managers. All observations of unfunded patient care services were recorded, numerically coded and descriptively analysed. Semi structured interviews were audio recorded and transcribed verbatim. A semantic thematic analysis was carried out. Appropriateness of study design was dictated by the ability to characterise services and obtain patient perceptions.
Results: Ten pharmacies took part in the feasibility study, across the city of Dunedin, New Zealand, representing a range of different practice settings and demographics. Ten patients were interviewed and six responded to follow up. Both pharmacy and patient recruitment proved challenging due to concerns around disruption to workflow and patient privacy. A continuous observation time motion study was found to be appropriate as it minimises disruption to workflow with no additional work required from the pharmacy teams.
Conclusions: A continuous observation time motion study proved to be an appropriate method to investigate the provision of unfunded services on a national scale. The findings of the study suggest design changes such as length of observation time, increasing patient recruitment and additional patient questions to enhance the nationwide study.
7
Donovan, Jacqueline, Ross T. Tsuyuki, Yazid N. Al Hamarneh, and Beata Bajorek. "Barriers to a full scope of pharmacy practice in primary care: A systematic review of pharmacists’ access to laboratory testing." Canadian Pharmacists Journal / Revue des Pharmaciens du Canada 152, no. 5 (August 6, 2019): 317–33. http://dx.doi.org/10.1177/1715163519865759.
Full textAbstract:
Objectives: To describe primary care pharmacists’ current scope of practice in relation to laboratory testing. Method: A 2-tiered search of key databases (PubMed, EMBASE, MEDLINE) and grey literature with the following MeSH headings: prescribing, pharmacist/pharmacy, laboratory test, collaborative practice, protocols/guidelines. We focused on Canada, the United States, the United Kingdom, New Zealand and Australia for this review. Results: There is limited literature exploring primary care pharmacists’ scope of practice in relation to laboratory testing. The majority of literature is from the United States and Canada, with some from the United Kingdom and New Zealand and none from Australia. Overall, there is a difference in regulations between and within these countries, with the key difference being whether pharmacists access and/or order laboratory testing dependently or independently. Canadian pharmacists can access and/or order laboratory tests independently or dependently, depending on the province they practise in. US pharmacists can access and/or order laboratory tests dependently within collaborative practice agreements. In the United Kingdom, laboratory testing can be performed by independent prescribing pharmacists or dependently by supplementary prescribing pharmacists. New Zealand prescribing pharmacists can order laboratory testing independently. Most publications do not report on the types of laboratory tests used by pharmacists, but those that do predominantly resulted in positive patient outcomes. Discussion/Conclusion: Primary care pharmacists’ scope of practice in laboratory testing is presently limited to certain jurisdictions and is often performed in a dependent fashion. As such, a full scope of pharmacy services is almost entirely unavailable to patients in the United States, the United Kingdom, New Zealand and Australia. Just as in the case for pharmacists prescribing, evidence indicates better patient outcomes when pharmacists can access/order laboratory tests, but more research needs to be done alongside the implementation of local guidelines and practice standards for pharmacists who practise in that realm. Patients around the world deserve to receive a full scope of pharmacists’ practice, and lack of access to laboratory testing is one of the major obstacles to this. Can Pharm J (Ott) 2019;152:xx-xx.
8
Tordoff, June, Michael Bagge, Farina Ali, Samira Ahmed, Jie Ning Choong, Rowena Fu, Annie Joe, and Prasad Nishtala. "Older people's perceptions of prescription medicine costs and related costs: a pilot study in New Zealand." Journal of Primary Health Care 6, no. 4 (2014): 295. http://dx.doi.org/10.1071/hc14295.
Full textAbstract:
INTRODUCTION: Older people tend to take more medicines and prescription medicine costs may influence medicine adherence. AIM: The aim of this pilot study was to identify older people's perceptions of prescription medicine costs and related costs in four major cities across New Zealand. METHODS: A questionnaire was administered to people aged 65 years and older visiting pharmacies in Auckland, Wellington, Christchurch, and Dunedin to identify their perceptions of costs relating to prescription medicines and related pharmacy and general practice services. Data were compared between cities and examined for associations between participants' views on costs and age, sex, income, ethnicity, number of medicines, and monthly cost. RESULTS: Participants (N=107) received a median of five prescription medicines (range 1–15), at a median cost of NZ$8.00 (range 0–55.30). Median part-charges for medicines only partly funded by the government were NZ$6.25 (range 0.60–100.00), and GP consultations ranged from NZ$0–60.00. Of the participants, 89 (83.2%) thought medicine costs and 63 (58.9%) thought GP consultation costs were reasonable. Participants with median monthly medicine costs of NZ$8.33–87.00 more commonly perceived medicines as expensive or very expensive (p=0.001, Fisher's exact test). DISCUSSION: Older people in this study mostly viewed their prescription medicines and related costs as reasonable; however, 17% and 41%, respectively, found medicines costs and GP consultation costs expensive. Larger, in-depth studies across New Zealand are needed to determine the sections of the population that find these costs expensive, and to explore how this might affect medicine adherence. KEYWORDS: Aged; community health services; costs and cost analysis; New Zealand; pharmaceutical preparations
9
Hikaka, Joanna, Carmel Hughes, Rhys Jones, Martin J. Connolly, and Nataly Martini. "A systematic review of pharmacist-led medicines review services in New Zealand – is there equity for Māori older adults?" Research in Social and Administrative Pharmacy 15, no. 12 (December 2019): 1383–94. http://dx.doi.org/10.1016/j.sapharm.2019.01.009.
Full text
10
Aspden, Trudi J., Pushkar R. Silwal, Munyaradzi Marowa, and Rhys Ponton. "Why do pharmacists leave the profession? A mixed-method exploratory study." Pharmacy Practice 19, no. 2 (June 3, 2021): 2332. http://dx.doi.org/10.18549/pharmpract.2021.2.2332.
Full textAbstract:
Background: Recent New Zealand policy documents aim for pharmacists to be retained, and promote the provision of extended clinical pharmacy services. However, younger pharmacists have expressed dissatisfaction with the profession on informal social for a.
Objectives: To explore the characteristics, and perspectives of pharmacy as a career, of recent Bachelor of Pharmacy (BPharm, four-year degree) graduates who have left, or are seriously considering leaving the New Zealand pharmacy profession in the near future and where they have gone, or plan to go.
Methods: We conducted a cross-sectional study with a mixed-method explanatory sequential design. An anonymous online survey among those who completed their pharmacy undergraduate degree (BPharm or equivalent) in 2003 or later and who had left or who were seriously considering leaving the New Zealand pharmacy profession in the next five years, was open from 1st December 2018 to 1st February 2019. Recruitment occurred via University alumni databases, pharmacy professional organisations, pharmaceutical print media, social media and word-of-mouth. Ten semi-structured interviews were then conducted with a purposive sample of survey respondents. Descriptive statistics were generated from the quantitative data and qualitative data were analysed using manifest content analysis.
Results: We received 327 analysable surveys of which 40.4% (n=132) were from those who had already left the New Zealand pharmacy sector at the time of the data collection and the rest (59.6% n=195) were those working within the sector, but seriously considering leaving the profession. Reasons most commonly reported for studying pharmacy were having an interest in health and wanting to work with people. The most common reasons for leaving, or wanting to leave, were dissatisfaction with the professional environment, including inadequate remuneration, and a perceived lack of career pathways or promotion opportunities. A wide range of career destinations were declared, with medicine being most frequently reported.
Conclusions: Most of the reasons for leaving/considering leaving the profession reported relate to the values and features of the pharmacy profession such as the professional environment, remuneration and career pathways. These findings are consistent with other studies and may represent a barrier to achieving the aims of recent health policy documents.
Dissertations / Theses on the topic "Pharmaceutical services New Zealand"
1
Tordoff, June Margaret, and n/a. "Evaluating the impact of a national hospital pharmaceutical strategy in New Zealand." University of Otago. School of Pharmacy, 2007. http://adt.otago.ac.nz./public/adt-NZDU20070712.151527.
Full textAbstract:
Background: In September 2001, in addition to their existing management of primary care pharmaceutical expenditure, PHARMAC, the New Zealand government�s Pharmaceutical Management Agency, was authorized to manage pharmaceutical expenditure in public hospitals.[1] In February 2002 PHARMAC launched a three-part Strategy, the National Hospital Pharmaceutical Strategy (NHPS), for this purpose.[2] The Strategy focused on Price Management (PM), the Assessment of New Medicines (ANM), and promoting Quality in the Use of Medicines (QUM). Major initiatives planned were: for PM, to negotiate new, national (as opposed to current, local) contracts for frequently used pharmaceuticals; for ANM, to provide economic assessments of new hospital medicines; and for QUM, to coordinate activities in hospitals.
Aims: To assess the impact of each of the three parts of the National Hospital Pharmaceutical Strategy, and assess any impact of the Strategy�s new contracts on the availability of those medicines.
Methods: Price Management was assessed in 2003, 2004 and 2005 using data from eleven selected hospitals to estimate savings for all 29 major hospitals, and by tracking hospital pharmaceutical expenditure from 2000 to 2006. For other aspects, cross-sectional surveys were administered to chief pharmacists at all hospitals employing a pharmacist; 30 hospitals in 2002, 29 in 2004. Surveys were undertaken in 2002 and 2004 to examine ANM and QUM activity in hospitals before and after the Strategy. Surveys were undertaken in 2004 and 2005 to examine any changes in the availability of medicines on new contracts, in hospitals. In 2005 a survey was undertaken of opinions on PHARMAC�s specially-developed pharmacoeconomic (PE) assessments.
Results: PM results indicated that, by 2006, savings of $7.84-13.45m per annum (6-8%) had been made on hospital pharmaceutical expenditure, and growth in inpatient pharmaceutical expenditure appeared to slow for all types of hospitals in 2003/4. ANM surveys indicated that, by 2004, hospital new medicine assessment processes, predominantly formal, became more complex, more focused on cost-effectiveness, and the use of pharmacoeconomic information increased. The PE survey indicated that PHARMAC�s economic assessments of new medicines were mainly viewed favourably but were not sufficiently timely to be widely used in hospital formulary decisions. Availability surveys indicated that new contracts occasionally caused availability problems e.g. products that were "out of stock", or products considered inferior by respondents. Problems were usually resolved within weeks, but some took over a year. QUM activities showed little change between surveys, but during the period an independent organisation was formed by the District Health Boards of New Zealand, with representation from PHARMAC, to coordinate the Safe and Quality Use of Medicines in New Zealand.
Conclusion: The National Hospital Pharmaceutical Strategy has been moderately successful in New Zealand. Savings of NZ$7.84-13.45m per annum were made, and growth in inpatient pharmaceutical expenditure appeared to slow in the year following the Strategy�s launch. The study has indicated some important short-term effects from the Strategy, but further research is needed to ensure that favourable effects are sustained and unfavourable effects kept to a minimum. Similar, centralized, multifaceted, approaches to managing pharmaceutical expenditure may be worth considering in other countries.
1. New Zealand Parliament. New Zealand Public Health and Disability Act. In: The Statutes of New Zealand 2000. No 91.Wellington: New Zealand Parliament; 2000
2. Pharmaceutical Management Agency. National Hospital Pharmaceutical Strategy Final Version. Wellington: PHARMAC; 2002
2
Smith, Mark Andrew. "Developing a recovery ethos for psychiatric services in New Zealand." The University of Waikato, 2007. http://hdl.handle.net/10289/2615.
Full textAbstract:
This thesis is about developing a recovery ethos for psychiatric services in New Zealand. The argument of the thesis is that currently a procedural ethos is dominant in psychiatric services in New Zealand, based on eclectic ways of facilitating recovery. Recovery from mental illness, is based on the criteria of symptom reduction and functioning and can be further refined to have a client and professional perspective. Rather than using an eclectic approach to facilitating recovery the thesis argues for a pluralistic approach, where the virtues, the relationship with professionals, client narrative and the psychiatric community become central to decision making, rather than principle based procedures. The thesis is an argued, applied philosophical thesis in terms of methodology. The scope of the thesis is psychiatric services and the focus is broadly ethical decision making. There are three main divisions to the thesis. Part 1 is concerned with clarification of the main terms used in the thesis. This involves exploring the historical background to the concept of recovery, clarifying the concept of recovery itself and providing an argument for giving greater prominence to the term mental illness over the term mental disorder. Part 2 identifies the main problem of the thesis, namely the procedural ethos, and the problems it is causing clients suffering from mental illness in facilitating their recovery. Part 3 shows what is involved in developing a recovery ethos for psychiatric services in New Zealand.
3
Neale, Ann Yvonne. "Factors related to the pricing of audit services in New Zealand." Thesis, University of Auckland, 1999. http://hdl.handle.net/2292/1105.
Full textAbstract:
Listed companies in New Zealand appoint an auditor, first, in compliance with statute mandatory appointment) and, second, to monitor agent (management) performance compared to principal (shareholder)preferences. The monitoring requirements of the audit contract should be reflected in the audit fee. In this thesis, I use Simunic's (1980) fee model to investigate three questions regarding the determinants of audit pricing. First, auditors have the incentive to earn fee premiums (quasi-rents) by developing specialised monitoring skills that address the needs of industries with a differentiated demand for monitoring. Three classifications of differentiated monitoring are developed to investigate whether fee premiums are earned on those audits. Fee premiums are shown to be earned by Big Seven auditors over non-Big Seven auditors, but the null hypothesis that industry specialist auditors do not earn fee premiums over non-specialists is not rejected. The incentive to earn quasi-rents in future fees provides a rationale for auditors to bid a reduced audit fee in order to gain incumbency (DeAngelo, 1981a). The second research question uses a sample of audit fees from the first financial statements after listing to test for reduced fees on initial audits. Results indicate that audit fees for the first financial statements after listing are lower than the level of audit fee for existing companies. Negotiation of audit fees may be affected by professional regulation. The third research question investigates whether abandonment of a fee scale by the professional accounting body in New Zealand influenced the general level of audit fees. The results fail to reject the null hypothesis that there is no difference in fees before and after abandonment of the fee scale. The incentive to develop industry-specialised monitoring skills may be replaced, in a small country, by alternate audit practice development strategies; for example, diversification of an audit portfolio in order to spread risk. Auditor brand name, reflecting technical skills, may thus earn a fee premium in preference to industry specialist skills. A final limitation of this work arises from the time period of interest (1985-87), a time of change in New Zealand's business environment, in which audit fee determinants may be subject to effects not captured in this thesis.
4
Hauraki, Jennifer. "A model minority?: Chinese youth and mental health services in New Zealand." Thesis, University of Auckland, 2005. http://hdl.handle.net/2292/1876.
Full textAbstract:
The 'model minority' label given to Chinese populations in New Zealand and other Western countries have made it difficult to truly comprehend the difficulties faced by some Chinese ethnic minorities. Despite comparable rates and types of mental health problems to their European counterparts, identifiable barriers have led to Chinese ethnic minorities underutilising mental health services. The present study investigated the mental health service utilisation in native- and foreign-born Chinese youth in New Zealand, paying particular attention to barriers to service utilisation and viable solutions for these difficulties. It consisted of three individual projects and explored the views of Chinese community and mental health professionals and Chinese university students, comparing their perspectives to university students of other ethnicities. Findings showed that despite a willingness to seek help from their family and mental health professionals (e.g., psychologists, school counsellors), respondents identified a myriad of obstacles to the help seeking of Chinese youth. These included physical barriers (e.g., financial and transport constraints), personal barriers (e.g., stigma, problems accepting their difficulties), service barriers (e.g., paucity of knowledge regarding mental health problems and available services) and family barriers (e.g., obstruction from family members). Family and service barriers distinguished the difficulties faced by Chinese in comparison to European youth, particularly with regards to the adherence of professionals to stereotypes of Chinese youth, a unique finding of this study. In order to reduce such barriers, the Chinese university students and professionals advocated for greater education regarding mental health problems and services in the Chinese community, education for Chinese parents regarding adolescent issues, an increase in the number of practicing Chinese professionals that is coupled with improved cross-cultural training for non-Chinese professionals, as well as individual assessment and treatment approaches with Chinese youth and their families.Whole document restricted, but available by request, use the feedback form to request access.
5
Edlin, Richard Paul. "Pharmaceutical subsidisation in New Zealand : a comparison of reference pricing with the Johnston-Zeckhauser scheme." Thesis, University of Canterbury. Economics and Finance, 1998. http://hdl.handle.net/10092/1998.
Full textAbstract:
An alternative scheme has been suggested to the reference pricing framework currently used in New Zealand. The subsidisation scheme outlined in Johnston, M and Zeckhauser, R. (1991) The Australian Pharmaceutical Subsidy Gambit: Transmuting Deadweight Loss and Oligopoly Rents to Consumer Surplus offers only the subsidy required to prompt acceptance of subsidisation by firms. This scheme is valid only where marginal costs are known. This thesis incorporates the creation of a framework for the comparison of pharmaceutical subsidy schemes, the expansion of the Johnston and Zeckhauser scheme into an environment of imperfect information, and the comparison of this modified scheme with the variant of reference pricing used in New Zealand. This comparison finds that the Johnston and Zeckhauser scheme generally provides subsidisation at a lower cost than reference pricing provided that a suitable threshold is placed on the time taken for a firm to accept subsidisation. Unfortunately the JZ scheme does not appear to provide a valid alternative to reference pricing as, on average, it is likely to promote a lower level of efficiency than the status quo. The thesis finds that reference pricing is however not without its problems, as the possibility exists that reference pricing will, in some cases, provide firms with less than the level of profit necessary to convince them to accept subsidisation.
6
Bromley, Helen. "Discourses and narratives of difference : 'race', rurality and illness : the case of the Hokianga, New Zealand." Thesis, University of Bristol, 1998. http://hdl.handle.net/1983/eaa176ee-c3f4-473a-971a-908d0c9afecb.
Full text
7
Alonso, Abel Duarte. "Wine tourism experiences in New Zealand: an exploratory study." Lincoln University, 2005. http://hdl.handle.net/10182/1046.
Full textAbstract:
Recently, New Zealand's wine industry has made remarkable progress. For example, the number of hectares planted in grapes increased from 4,880 in 1990, to 15,479 in 2003, and the number of wineries increased from 175 in 1993 to 421 in 2003. Projections for 2006 indicate that the growth of wine exports should nearly double from 2003, with expected revenues of $NZ 736 million. However, despite this growth, little has been reported about developments in New Zealand's wine tourism industry, or about consumer perceptions of the winery experience in the form of published academic research. The limited amount of information, particularly from the visitors' points of view, may not only be preventing winery operators and the wine industry in general from having a better understanding of their visitors, but also from addressing the needs of different visitor segments. Resulting implications for winery operators may include forgone business opportunities, and customers not fully benefiting in terms of product and service quality. Recent studies indicate that this last element is particularly important in wine tourism. This study reports the results of an exploratory research project conducted in New Zealand wineries that investigated aspects of the winery experience, including wine involvement, satisfaction with the winery experience, and visitor demographics. An index to measure involvement with wine, the wine involvement index (WIX), was developed and utilised to investigate whether wine involvement had an impact on winery visitors' behaviour. Data were collected from winery visitors via questionnaires distributed in a sample of wineries in different wine regions of New Zealand. A total of 609 usable responses were obtained (24.8% response rate). The results indicate a number of differences between the independent, dependent, and moderating variables. For example, it was found that age, whether visitors are domestic or international, and different levels of wine involvement appear to have a clear impact on winery expenditure. In addition, the WIX was confirmed to be a useful tool, for example, by identifying potential relationships between different groups of winery visitors. The results add new knowledge to the area of wine tourism, and offer useful information for wineries and the wine tourism industry. This information includes the potential commercial significance of some visitor groups. An additional contribution of this study is the 'complete wine tourism research model.' This concept presents an alternative to existing wine tourism models, and points out attributes and dimensions that play a major role in the winery experience.
8
Joudi, Kadri Rose. "Resettling the Unsettled: The Refugee Journey of Arab Muslims to New Zealand." AUT University, 2009. http://hdl.handle.net/10292/988.
Full textAbstract:
Since the 1980s, nearly 5000 Arab and Muslim refugees have been resettled in New Zealand (RefNZ, 2007) as a result of political instability and wars that have riddled the Arabic-speaking region. Upon arrival in a resettlement country, refugees face many challenges in adjusting to their new environment (Simich et al., 2006; Valtonen, 1998). Arab Muslim refugees have specific concerns that are different to other refugee groups due to the major role Islam plays in the way Muslim people go about their lives, and due to the controversial image of Muslims in Western countries since the September 11th (USA) and July 7th (London) bombings. To date, relatively little attention has been paid to the various ongoing resettlement issues that these refugees deal with. This research attempts to fill in some of these gaps by addressing the resettlement experiences of Arab Muslim refugees in New Zealand. It is expected that this research will assist the policy making and migrant services sector (a) to understand the refugees' lived realities; (b) to confront the stereotypes associated with refugees in general, and the stereotypes associated with Arab Muslim refugees in particular; and (c) to address the issues and challenges faced by Arab Muslim refugees. The significance of this research is located in its potential to influence policy and practice in the fields of refugee resettlement, immigration, and counselling. In addition, this study will contribute to knowledge about Arab Muslim refugees, especially those living in New Zealand. Recently, studies in the fields of sociology, anthropology, and psychology on refugees and refugee resettlement have found that non-Western refugees experience a variety of resettlement and adjustment challenges when settling in Western societies. However, intensive research is needed on refugees' perspectives on their refugee journey, their resilience during resettlement, and the experiences that accompany the refugee journey. A deepened understanding of the phenomenon of the refugee journey may contribute to the development of appropriate support for refugees and foster welcoming host societies. It is therefore anticipated that this study of the refugee experiences of Arab Muslims will add to existing research on refugee resettlement and in particular Arab Muslim refugees in Western societies. Semi-structured, face to face interviews were conducted with 31 male and female Arabic-speaking Muslim refugees from Iraq, Sudan, Somalia, Kuwait, and Tunisia. The participants had been "resettled" in New Zealand for at least six months and up to eleven years. Most of the interviews were conducted in Arabic and then translated to English. The interviews were analysed using an eclectic approach including thematic analysis with elements of life story narratives. The findings that emerged from this research suggest that whatever the national and ethnic background of the refugee, there are common key issues and themes relating to the refugee journey and the challenges experienced by refugees during their resettlement. The interviews revealed participants' experiences of their lives as refugees, which were described in three separate stages that I have termed the "three legs of the refugee journey." The first leg of the refugee journey included the refugees' pre-migration experience: reasons for fleeing their homelands, becoming a refugee, and the impact of the refugee label on their lives in their resettlement country. The second leg of the refugee journey involved their experiences in adjusting to their 'new' lives after leaving Mangere Refugee Resettlement Centre (MRRC): their experiences with several resettlement agencies in NZ, their unforeseen resettlement challenges such as language barriers, unemployment, and their concern over raising their children in a non-Muslim society. The third leg uncovered the experiences participants went through after one year of their initial resettlement, and also explored methods of coping and resilience that participants used to overcome their ongoing resettlement challenges and mental health concerns, and their perspective on New Zealand as a resettlement country. This leg also included the participants' future aspirations and their long-term resettlement plans. Overall, participants were unprepared for the situation that faced them when they arrived in New Zealand. Their experience in the six weeks at the resettlement centre was disappointing for all of them and traumatic for some. Participants did not feel that they were equipped with "survival skills" for dealing with life outside the centre. All participants expressed that they had difficulties adjusting to their new life in New Zealand. In general, women found adjustment more difficult than men. Some participants expressed gratitude to New Zealand for accepting them as refugees. A minority were happy to remain in New Zealand, the majority were reluctant about staying, and a small number intended to return to their homeland or other Arab Muslim countries as soon as they could. It is significant that for the participants in this study, their identity as a refugee had an overwhelming impact on the way they talked about their lives. Participants had the perception that being labelled as refugees was a factor that alienated them from New Zealand society. Also, being Arab and Muslim as well as a refugee was seen as an additional disadvantage for resettlement opportunities in New Zealand and other Western countries. While Arab Muslim refugees share many of the concerns of other refugees, there are particular issues, including the challenge of maintaining their religious and cultural traditions, which they experienced as being in conflict with resettling in a Western country. Despite the fact that New Zealand has a long history in assisting in the resettlement of refugees, this research reinforces previous research in New Zealand which points to the inadequacies of the resettlement experience for refugees during all three legs of the refugee journey. The thesis therefore concludes with recommendations for improving refugee policies and services.
9
White, Jill Fredryce. "The commodification of caring : a search for understanding of the impact of the New Zealand health reforms on nursing practice and the nursing profession : a journey of the heart /." Title page, table of contents and abstract only, 2004. http://web4.library.adelaide.edu.au/theses/09PH/09phw5822.pdf.
Full text
10
Poa, Nicola. "Molecular Genetics of Type 2 Diabetes in New Zealand Polynesians." Thesis, University of Auckland, 2004. http://hdl.handle.net/2292/692.
Full textAbstract:
The risk of developing type 2 diabetes is four fold higher in New Zealand(NZ) Polynesians compared to Caucasians. Hence diabetes is more prevalent in Maori (16.5% of the general population) and Pacific Island people (10.1%) compared to NZ Caucasians (9.3%). It is generally accepted that type 2 diabetes has major genetic determinants and heterozygous mutations in a number of genes have previously been identified in some subsets of type 2 diabetes and certain ethnic groups. The high prevalence of diabetes in NZ Polynesians, when compared with NZ Caucasians, after controlling for age, income and body mass index (BMI), suggest that genes may be important in this population. Therefore, the prevalence of allelic variations in the genes encoding amylin and insulin promoter factor-1 (IPF-1), and exon 2 of the hepatocyte nuclear factor-1α (HNF-1α) gene in NZ Polynesians with type 2 diabetes was determined. These genes are known to produce type 2 diabetes in other populations. The genes investigated were screened for mutations by PCR amplification and direct sequencing of promoter regions, exons and adjacent intronic sequences from genomic DNA. DNA was obtained from 146 NZ Polynesians (131 Maori and 15 Pacific Island) with type 2 diabetes and 387 NZ Polynesian non-diabetic control subjects (258 Maori and 129 Pacific Island). Sequences were compared to previously published sequences in the National Centre for Biotechnology Information database. Allelic variations in IPF-1 and exon 2 of the HNF-1α gene were not associated with type 2 diabetes in NZ Polynesians. However, in the amylin gene, two new and one previously described allele was identified in the Maori population including: two alleles in the promoter region (-132G>A and -215T>G), and a missense mutation in exon 3 (QlOR). The -215T>G allele was observed in 5.4% and l% of type 2 diabetic and non-diabetic Maori respectively, and predisposed the carrier to diabetes with a relative risk of 7.23. The -215T>G allele was inherited with a previously described amylin promoter polymorphism(-230A>C) in 3% of Maori with type 2 diabetes, which suggests linkage equilibrium exists between these two alleles. Both Q10R and -132G>A were observed in 0.76% of type 2 diabetic patients and were absent in non-diabetic subjects. Together these allelic variations may account for approximately 7% of type 2 diabetes in Maori. These results suggest that the amylin gene maybe an important candidate marker gene for type 2 diabetes in Maori.
Books on the topic "Pharmaceutical services New Zealand"
1
Parker, J. E. S. Pharmaceutical patents in New Zealand. Auckland, N.Z: IMS (N.Z.) Ltd., 1991.
Find full text
2
Zealand, New. New Zealand goods and services tax legislation. 7th ed. Auckland: CCH New Zealand, 1993.
Find full text
3
Starchild, Adam. The New Zealand immigration guide. Port Townsend, Wash: Loompanics Unlimited, 1997.
Find full text
4
Dymond, John. Ecosystem services in New Zealand: Conditions and trends. Lincoln, New Zealand: Manaaki Whenua Press, 2013.
Find full text
5
Roberts, H. S. A history of statistics in New Zealand. Wellington, N.Z: New Zealand Statistical Association, 1999.
Find full text
6
John, Savage. Financial centre prospects for New Zealand. Wellington, N.Z: N.Z. Institute of Economic Research, 1988.
Find full text
7
Cullen, Rowena. Public library effectiveness: A New Zealand study. Wellington: Dept. of Library and Information Studies, Victoria University of Wellington, 1992.
Find full text
8
New Zealand. Office of the Auditor-General. Immigration New Zealand: Supporting new migrants to settle and work. Wellington: Office of the Auditor General, 2013.
Find full text
9
Gifford, D. J. Directory of metallurgical services and facilities in New Zealand. Wellington: Science Information Pub. Centre, DSIR, 1985.
Find full text
10
New Zealand. Office of the Auditor-General. Setting up Central Agencies Shared Services. Wellington: Office of the Auditor-General, 2014.
Find full textBook chapters on the topic "Pharmaceutical services New Zealand"
1
Ragupathy, Rajan, Kate Kilpatrick, and Zaheer-Ud-Din Babar. "Pharmaceutical Pricing in New Zealand." In Pharmaceutical Prices in the 21st Century, 189–207. Cham: Springer International Publishing, 2014. http://dx.doi.org/10.1007/978-3-319-12169-7_11.
Full text
2
Pallot, Marie, and Thomas Allen. "Loan Intermediary Services: New Zealand." In VAT and Financial Services, 159–68. Singapore: Springer Singapore, 2017. http://dx.doi.org/10.1007/978-981-10-3465-7_10.
Full text
3
Chen, Timothy F., and Prasad S. Nishtala. "Pharmaceutical Care in Australia and New Zealand." In The Pharmacist Guide to Implementing Pharmaceutical Care, 173–82. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-92576-9_15.
Full text
4
Toime, Elmar, and Ian Steele. "Competitive Strategy for New Zealand Post." In Competition and Innovation in Postal Services, 275–85. Boston, MA: Springer US, 1991. http://dx.doi.org/10.1007/978-1-4757-4818-5_13.
Full text
5
Abel, Gillian, and Catherine Healy. "Sex Worker-Led Provision of Services in New Zealand: Optimising Health and Safety in a Decriminalised Context." In Sex Work, Health, and Human Rights, 175–87. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-64171-9_10.
Full textAbstract:
AbstractDecriminalisation recognises sex work as work; it provides opportunities for promoting the health of sex workers and therefore goes a long way to addressing health and human rights inequities for this sector of the population. This chapter focuses on three scenarios (among many) where decriminalisation of sex work in New Zealand has been successful in promoting sex workers’ health, safety, and wellbeing and, in so doing, provides a blueprint for best practice in working with sex workers.Although services for sex workers are available in many countries, they tend to focus on street-based sex workers, who are perceived as the most vulnerable and thus most in need. A decriminalised context provides greater access to peer support (Harcourt 2010), which is much better positioned to address the complex needs of all sex workers. It also allows for sex workers to engage with others in the community for more effective policy as well as service provision (O’Neill and Pitcher, Sex work matters: exploring money, power and intimacy in the sex industry, Zed Books, London, 2010). In this chapter, we discuss: How access to police has been improved for sex workers who wish to report sexual assault How decriminalisation has enabled interagency collaboration when working with sex workers who have concerns about practices within certain brothels How new sex workers access information on safe practices in a decriminalised environment We use the research literature from New Zealand and elsewhere to expand on the real-life stories of the engagement between New Zealand Prostitutes Collective and sex workers, agencies, and individuals to illustrate the three scenarios.
6
Green, Nicola, David Tappin, and Tim Bentley. "The Impact of Telehealth Video-Conferencing Services on Work Systems in New Zealand: Perceptions of Expert Stakeholders." In Advances in Intelligent Systems and Computing, 192–97. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-96098-2_25.
Full text
7
Chew, Lita, and Miko Chui Mei Thum. "Pharmacy Requirements for a Comprehensive Cancer Center." In The Comprehensive Cancer Center, 75–83. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-82052-7_9.
Full textAbstract:
AbstractA pharmacy in a comprehensive cancer center needs to be cognizant of new and emerging models of care that are integrated and patient-centered, attentive to cutting edge research, cancer treatment and different approaches to managing the entire spectrum of oncological care. Hence, the focus of pharmacy services should be on care deliverance that is timely and convenient, affordable and financially sustainable to fulfill quality assured pharmaceutical needs.The prerequisites to transformation from a brick-and-mortar pharmacy model to a progressive pharmacy is guided by the perspectives of investing in (1) human capital to retain and attract the best, (2) place to build a future-ready facility, (3) process to create greater value for patients by producing safe and quality products. The authors share their experience along these perspectives: a focus on staff development, training and well-being; a facility leveraging on automation, good manufacturing practice, and business continuity planning; processes to support medication use and new models of care.Technological disrupters such as the internet, social media, and AI are also changing the fabric of society. While future events may not take same form, they will require a deliberate effort from organization to navigate effectively and with agility. This chapter will also address the key considerations for a sustainable pharmacy in terms of self, environment and financial sustainability.
8
Thompson, Mike. "New Zealand." In International Pharmaceutical Registration. Informa Healthcare, 2000. http://dx.doi.org/10.1201/9781420026061.ch18.
Full text
9
"New Zealand." In Services Profiles, 100. WTO, 2015. http://dx.doi.org/10.30875/d4b7b665-en.
Full text
10
"New Zealand." In Services Profiles, 129. WTO, 2015. http://dx.doi.org/10.30875/d53b066a-en.
Full textConference papers on the topic "Pharmaceutical services New Zealand"
1
Gu, Yulong, and James Warren. "Towards Analysing Information Management Requirements in New Zealand Genetic Services." In 2008 15th Asia-Pacific Software Engineering Conference. IEEE, 2008. http://dx.doi.org/10.1109/apsec.2008.65.
Full text
2
Wilson, Holly, and Liesje Donkin. "UNDERSTANDING NEW ZEALAND ADULTS’ ATTITUDES TOWARDS DIGITAL INTERVENTIONS FOR HEALTH." In International Psychological Applications Conference and Trends. inScience Press, 2021. http://dx.doi.org/10.36315/2021inpact011.
Full textAbstract:
"E-health has transformed healthcare by improving access and reach of health services, which is now more critical than ever given the COVID-19 pandemic. One aspect of e-health is the delivery of health interventions via the internet or through smartphone apps, known as digital interventions (DI). These DI can improve physical and mental health for people, by modifying behaviour and improving illness management. Despite, the benefits of DI use remains low. One explanation for this low usage is people’s attitudes towards DI. Indeed, having a positive attitude towards DI is associated with an increased likelihood of wanting to engage with DI. Therefore, people’s attitudes towards digital interventions are important in understanding if people are willing to engage with them. To date, limited research exists about attitudes and much of this varies based on region and population. Along, with understanding people’s attitudes it is important to understand what shapes people’s attitudes towards these interventions. Therefore, this study sought to determine New Zealand (NZ) adults’ attitudes towards DI and what shapes these attitudes. In order to address these questions a cross-sectional survey was used. Results indicate that NZ adults have neutral to somewhat positive attitudes to DI and their attitudes are influenced by common factors including: beliefs about accessibility of DI and the COVID-19 experience. These findings suggest that some NZ adults have a positive attitudes to DI, but overall people’s attitudes needed to be addressed to ensure people are ready to use DI."
3
Tallon, Rachel, and Joey Domdom. "Navigating Tensions in the Secular Workplace by Christians in the Social Services: Findings from an Aotearoa New Zealand Study." In 2021 ITP Research Symposium. Unitec ePress, 2022. http://dx.doi.org/10.34074/proc.2205015.
Full textAbstract:
The social services are a value-laden field of employment as work involves frequent ethical decision-making around issues that relate to values, such as end of life, sexuality and so forth. Tensions can exist between individual practitioners, their employment agency and society, concerning ethics and values. This paper presents partial findings from a qualitative study that explored the tensions or issues faced by 16 Christian social-service practitioners working in non-faith-based settings by asking the question, “What tensions do Christian practitioners face in secular organisations?” In particular, we present themes from the findings that show utilisation of Indigenous cultural and/or spiritual practices to strengthen faith and work. The context is Aotearoa New Zealand, where there are unique relationships between religions (both from colonial settlers and Indigenous people), spirituality, secularism and the provision of social services. How these various aspects intersect and affect the Christian practitioner was of interest to this study. This paper may contribute to further research concerning the use of Indigenous practices in modern social services and healthcare.
4
Lilley, Rebbecca, Bridget Kool, Brandon de Graaf, Gabrielle Davie, Shanthi Ameratunga, Papaarangi Reid, Ian Civil, Bridget Dicker, and Charles Branas. "PW 1340 A geospatial examination of access to advanced trauma services in new zealand: identifying opportunities to improve survival following serious injury." In Safety 2018 abstracts. BMJ Publishing Group Ltd, 2018. http://dx.doi.org/10.1136/injuryprevention-2018-safety.689.
Full text
5
Nagy, Diána. "Possibilities of Digitalization and Service Design in the Development of Patient Adherence." In New Horizons in Business and Management Studies. Conference Proceedings. Corvinus University of Budapest, 2021. http://dx.doi.org/10.14267/978-963-503-867-1_05.
Full textAbstract:
In parallel with the development of modern health systems and the growth of the welfare state, diseases have shifted towards chronic diseases. Today, instead of rapid-onset infections, most resources are focused on the long-term treatment of mostly lifelong chronic conditions. The condition for the effective use of therapies is to take the specified dose with the prescribed frequency and for the required period of time. If these parameters are met, we can talk about patient collaboration or adherence. For certain diseases and treatments, adherence is critically low. In the case of complex preparations to be taken several times a day, or diseases that do not cause serious, noticeable complaints, the initial number of patients treated is reduced to a fraction within a short time. As a result, economic harm is perceived not only by the patient but also by all those involved in the health care system, including pharmaceutical companies. However, the factors influencing patient collaboration vary widely. In order to achieve high adherence, the goal is to develop health services that coordinate the actors involved, the infrastructure, the communication, the material components to improve the user experience. As a user-centered methodology, service design can play a prominent role in the design of therapeutic services, contributing to the reduction of uncertainties in innovation processes. In my study, I assess the digital toolkit of patient education in Hungarian society. The aim is to explore digital tools and technologies that can contribute to the development of health awareness and education so that both science and the pharmaceutical and technology companies that exploit it can apply the results of research.
6
"Proceedings V International Workshop on Rational Use of Medicines; III Worknowledge of Evidence-Informed Police; III Symposium ISPE BrazIntRIG; I Symposium of ISPE Brazilian Student Chapters." In V International Workshop on Rational Use of Medicines; III Worknowledge of Evidence-Informed Police; III Symposium ISPE BrazIntRIG; I Symposium of ISPE Brazilian Student Chapters. Brazilian Journal of Pharmaceutical Sciences, 2021. http://dx.doi.org/10.46943/v.iwrum.2021.02.
Full textAbstract:
Producing and sharing knowledge have been the main goals of the Graduate Program in Pharmaceutical Sciences of the University of Sorocaba. With a focus on the rational use of medicines, the importance of the event is justified by highlighting one of the main concerns worldwide, with an important impact on society, health systems, institutions, and communities. The improvement of professional practices depends on the engagement of researchers, health professionals, managers, students, and others interested in improving health policies, programs, services, and actions. Developing and applying scientific methods in producing and using the best evidence is the path we have chosen. Therefore, everyone was invited to discuss relevant topics in this field of knowledge, including Drug Utilization Research; Health Technology Assessment; Global Health Systems and Environment; and Innovation and Development of Health Technologies. Experts from several countries in deprescribing, interactive teaching approaches, implementation science and policy, environment and pharmaceutical care joined us sharing their experiences and encouraging debate. We are sure that the social distancing, essential in this period, did not represent an obstacle in making new connections, and effective and bright collaborations that are able to transform reality.
7
Lopes, Luciane Cruz. "Anais do V International Workshop on Rational Use of Medicines." In V International Workshop on Rational Use of Medicines. Brazilian Journal of Pharmaceutical Science, 2021. http://dx.doi.org/10.46943/v.iwrum.2021.01.
Full textAbstract:
Producing and sharing knowledge have been the main goals of the Graduate Program in Pharmaceutical Sciences of the University of Sorocaba. With a focus on the rational use of medicines, the importance of the event is justified by highlighting one of the main concerns worldwide, with an important impact on society, health systems, institutions, and communities. The improvement of professional practices depends on the engagement of researchers, health professionals, managers, students, and others interested in improving health policies, programs, services, and actions. Developing and applying scientific methods in producing and using the best evidence is the path we have chosen. Therefore, everyone was invited to discuss relevant topics in this field of knowledge, including Drug Utilization Research; Health Technology Assessment; Global Health Systems and Environment; and Innovation and Development of Health Technologies. Experts from several countries in deprescribing, interactive teaching approaches, implementation science and policy, environment and pharmaceutical care joined us sharing their experiences and encouraging debate. We are sure that the social distancing, essential in this period, did not represent an obstacle in making new connections, and effective and bright collaborations that are able to transform reality
8
Gentili, Enzo, Francesco Aggogeri, and Marco Mazzola. "The Effectiveness of the Quality Function Deployment in Managing Manufacturing and Transactional Processes." In ASME 2007 International Mechanical Engineering Congress and Exposition. ASMEDC, 2007. http://dx.doi.org/10.1115/imece2007-43448.
Full textAbstract:
The goal of Quality Engineering is to design quality into every product, service and manufacturing process. In particular a methodology is claimed to be very important for Quality design and management: Quality Function Deployment (QFD). QFD is a structured methodology and mathematical tool used to identify and quantify customer requirements and translate them into key critical parameters of systems and processes. The aim of the paper is to show how a quality management approach can support the increase of the process capability in a global vision of every business. QFD represents one of the most successful tools used in industrial management. By using actual and real cases, the paper shows the effectiveness of the QFD in improving both the management of a process and its capability. Four examples are presented. They take into account different environments: pharmaceutical, mechanical, healthcare and transportation markets. The first case study is deployed in a pharmaceutical company to satisfy the new customer requirements for the introduction of a nasal spray product on the Japanese market. The second example is applied to the automotive market for the production of air-cooling devices for deluxe vehicles. Finally, the other two cases show the implementation of the QFD tool in transactional processes, such as Cargo Center activities and healthcare services.
9
Smith, Valance, James Smith-Harvey, and Sebastian Vidal Bustamante. "Ako for Niños: An animated children’s series bridging migrant participation and intercultural co-design to bring meaningful Tikanga to Tauiwi." In LINK 2021. Tuwhera Open Access, 2021. http://dx.doi.org/10.24135/link2021.v2i1.142.
Full textAbstract:
This presentation advances a case study for an ongoing intercultural animation project which seeks to meaningfully educate New Zealand Tauiwi (the country's diverse groups, including migrants and refugees) on the values, customs and protocols (Tikanga) of Māori (the indigenous people of Aotearoa New Zealand). Ako For Niños (‘education for children’), implemented by a migrant social services organisation and media-design team, introduces Latin American Tauiwi to Tikanga through an animated children’s series, developed with a community short story writing competition and co-design with a kaitiaki (Māori guardian/advisor). Māori are recognised in Te Tiriti o Waitangi (the founding document of New Zealand) as partners with Pākeha (European New Zealanders), and Māori knowledge and Tikanga are important to society and culture in Aotearoa. Notwithstanding, there has been a historic lack of attention paid to developing meaningful understandings of Māori perspectives for New Zealand Tauiwi. Ako For Niños endeavours to address current shortages of engaging resources on Māori worldviews for Tauiwi communities, create opportunities for Tauiwi to benefit from Māori epistemologies, and foster healthy community relationships between Māori and Latin American Tauiwi. Through the project’s short story competition, Tauiwi were given definitions of Tikanga through a social media campaign, then prompted to write a children’s tale based on one of these in their native language. This encouraged Tauiwi to gain deeper comprehension of Māori values, and interpret Tikanga into their own expressions. Three winning entries were selected, then adapted into stop-motion and 2D animations. By converting the stories into aesthetically pleasing animated episodes, the Tikanga and narratives could be made more captivating for young audiences and families, appealing to the senses and emotions through visual storytelling, sound-design, and music. The media-design team worked closely with a kaitiaki during this process to better understand and communicate the Tikanga, adapting and co-designing the narratives in a culturally safe process. This ensured Māori knowledge, values, and interests were disseminated in correct and respectful ways. We argue for the importance of creative participation of Tauiwi, alongside co-design with Māori to produce educational intercultural design projects on Māori worldviews. Creative participation encourages new cultural knowledge to be imaginatively transliterated into personal interpretations and expressions of Tauiwi, allowing indigenous perspectives to be made more meaningful. This meaningful engagement with Māori values, which are more grounded in relational and human-centred concepts, can empower Tauiwi to feel more cared for and interconnected with their new home and culture. Additionally, co-design with Māori can help to honour Te Tiriti, and create spaces where Tauiwi, Pākeha and Māori interface in genuine partnership with agency (rangatiratanga), enhancing the credibility and value of outcomes. This session unpacks the contexts informing, and methods undertaken to develop the series, presenting current outcomes and expected directions (including a screening and exhibition). We will also highlight potential for the methodology to be applied in new ways in future, such as with other Tauiwi communities, different cultural knowledge, and increased collaborative co-design with Māori.
10
Sika, Peter. "POTENTIAL FOR THE DEVELOPMENT OF THE SILVER ECONOMY UNDER THE CONDITIONS OF THE SLOVAK REPUBLIC." In 4th International Scientific Conference – EMAN 2020 – Economics and Management: How to Cope With Disrupted Times. Association of Economists and Managers of the Balkans, Belgrade, Serbia, 2020. http://dx.doi.org/10.31410/eman.2020.81.
Full textAbstract:
The economic behaviour, needs and preferences of people vary in the individual phases of their lives. The silver economy market is made up of consumers, employees or employers aged 50+. The share of this population is an important target group for entrepreneurs, brings a wide range of new products and services to businesses and has a significant role for the national economy as there is a change in the understanding of the ageing process from a threat towards economic opportunities. Although the ageing workforce and seniors in the Slovak Republic do not represent a strong demand for market goods yet, their economic potential may not be negligible. The rapid ageing of the Slovak population represents, among other things, an economic potential that can be exploited in favour of innovation and improvement. Despite not a high level of pensions, seniors have considerable purchasing power, which will generate an increasing demand for specific goods and services, which is an opportunity for the labour market. In this paper we try to describe selected areas in which the silver economy and the ageing population itself should be viewed as a challenge to new business opportunities. In particular, these include health service and health care, spa care, the pharmaceutical industry, tourism, the financial sector and, last but not least, construction industry. The silver economy will change the rules of market forces in existing sectors and create a wholly new industry at the intersection of demographic and technological changes with a high export potential.
Reports on the topic "Pharmaceutical services New Zealand"
1
Tóth, Attila, and Richard T. Yao. Cultural Ecosystem Services and Water Quality Improvement provided by Forest Landscapes in New Zealand. Scientific Report. Scion, New Zealand & Slovak University of Agriculture in Nitra, Slovakia, June 2019. http://dx.doi.org/10.15414/2019.9780473480899.
Full text
2
Hall, David. Adaptation Finance: Risks and Opportunities for Aotearoa New Zealand. Mōhio Research and Auckland University of Technology (AUT), November 2022. http://dx.doi.org/10.24135/10292/15670.
Full textAbstract:
Methodology: This report was developed through the co-design process of Mōhio’s Climate Innovation Lab, a fixed-term initiative which works with stakeholders to envision financial instruments to mobilise capital for climate-aligned projects and activities. A working paper was prepared through international market scanning and a review of primary and secondary literature on climate adaptation. This working paper became the basis for a workshop with local experts and stakeholders to test the viability of potential instruments in light of Aotearoa New Zealand’s unique cultural, biophysical and regulatory context. The workshop included participants from finance services, insurance, institutional investment, academia and local and central government observers. These insights were reincorporated into this final concept paper. Mōhio would like to thank the workshop participants for their time and expertise.
3
Shey Wiysonge, Charles. What are the benefits and harms of direct to consumer advertising? SUPPORT, 2016. http://dx.doi.org/10.30846/160805.
Full textAbstract:
Direct to consumer advertising is increasingly used by the pharmaceutical industry and its merits have been extensively debated. Regulations related to such advertising vary: in New Zealand and the United States of America (USA), for example, regulations do not explicitly prohibit such advertising and its use has grown. In other countries, however, the practice has been banned and heavy lobbying by the pharmaceutical industry has been resisted.
4
Jauny, Ray, and John Parsons. Delirium Assessment and Management: A qualitative study on aged-care nurses’ experiences. Unitec ePress, November 2017. http://dx.doi.org/10.34074/ocds.72017.
Full textAbstract:
Aged residential care (ARC) residents with morbid health conditions frequently experience delirium. This condition is associated with diminished quality of life, preventable morbidity and untimely death. It is challenging and costly to manage delirium because of the complex interplay of physical and psychiatric symptoms associated with this condition in both primary and secondary services. With awareness of risk factors and knowledge about delirium, ARC nurses can play a vital role in early identification, assessment and treatment, but most importantly in preventing delirium in aged-care residents as well as improving health outcomes. Focus groups were carried out with ARC nurses to ascertain their opinions on how they assess and manage delirium in ARC facilities in South Auckland, New Zealand. Findings identified that there were strengths and weaknesses, as well as gaps in assessment and management of delirium. Nurses would benefit from delirium education, appropriate tools and adequate resources to help them manage delirium. Issues with diagnosing delirium, anxiety about challenging behaviours, family dynamics, lack of training and absence of IV treatment were noticeable features in this study.
5
Smit, Amelia, Kate Dunlop, Nehal Singh, Diona Damian, Kylie Vuong, and Anne Cust. Primary prevention of skin cancer in primary care settings. The Sax Institute, August 2022. http://dx.doi.org/10.57022/qpsm1481.
Full textAbstract:
Overview Skin cancer prevention is a component of the new Cancer Plan 2022–27, which guides the work of the Cancer Institute NSW. To lessen the impact of skin cancer on the community, the Cancer Institute NSW works closely with the NSW Skin Cancer Prevention Advisory Committee, comprising governmental and non-governmental organisation representatives, to develop and implement the NSW Skin Cancer Prevention Strategy. Primary Health Networks and primary care providers are seen as important stakeholders in this work. To guide improvements in skin cancer prevention and inform the development of the next NSW Skin Cancer Prevention Strategy, an up-to-date review of the evidence on the effectiveness and feasibility of skin cancer prevention activities in primary care is required. A research team led by the Daffodil Centre, a joint venture between the University of Sydney and Cancer Council NSW, was contracted to undertake an Evidence Check review to address the questions below. Evidence Check questions This Evidence Check aimed to address the following questions: Question 1: What skin cancer primary prevention activities can be effectively administered in primary care settings? As part of this, identify the key components of such messages, strategies, programs or initiatives that have been effectively implemented and their feasibility in the NSW/Australian context. Question 2: What are the main barriers and enablers for primary care providers in delivering skin cancer primary prevention activities within their setting? Summary of methods The research team conducted a detailed analysis of the published and grey literature, based on a comprehensive search. We developed the search strategy in consultation with a medical librarian at the University of Sydney and the Cancer Institute NSW team, and implemented it across the databases Embase, MEDLINE, PsycInfo, Scopus, Cochrane Central and CINAHL. Results were exported and uploaded to Covidence for screening and further selection. The search strategy was designed according to the SPIDER tool for Qualitative and Mixed-Methods Evidence Synthesis, which is a systematic strategy for searching qualitative and mixed-methods research studies. The SPIDER tool facilitates rigour in research by defining key elements of non-quantitative research questions. We included peer-reviewed and grey literature that included skin cancer primary prevention strategies/ interventions/ techniques/ programs within primary care settings, e.g. involving general practitioners and primary care nurses. The literature was limited to publications since 2014, and for studies or programs conducted in Australia, the UK, New Zealand, Canada, Ireland, Western Europe and Scandinavia. We also included relevant systematic reviews and evidence syntheses based on a range of international evidence where also relevant to the Australian context. To address Question 1, about the effectiveness of skin cancer prevention activities in primary care settings, we summarised findings from the Evidence Check according to different skin cancer prevention activities. To address Question 2, about the barriers and enablers of skin cancer prevention activities in primary care settings, we summarised findings according to the Consolidated Framework for Implementation Research (CFIR). The CFIR is a framework for identifying important implementation considerations for novel interventions in healthcare settings and provides a practical guide for systematically assessing potential barriers and facilitators in preparation for implementing a new activity or program. We assessed study quality using the National Health and Medical Research Council (NHMRC) levels of evidence. Key findings We identified 25 peer-reviewed journal articles that met the eligibility criteria and we included these in the Evidence Check. Eight of the studies were conducted in Australia, six in the UK, and the others elsewhere (mainly other European countries). In addition, the grey literature search identified four relevant guidelines, 12 education/training resources, two Cancer Care pathways, two position statements, three reports and five other resources that we included in the Evidence Check. Question 1 (related to effectiveness) We categorised the studies into different types of skin cancer prevention activities: behavioural counselling (n=3); risk assessment and delivering risk-tailored information (n=10); new technologies for early detection and accompanying prevention advice (n=4); and education and training programs for general practitioners (GPs) and primary care nurses regarding skin cancer prevention (n=3). There was good evidence that behavioural counselling interventions can result in a small improvement in sun protection behaviours among adults with fair skin types (defined as ivory or pale skin, light hair and eye colour, freckles, or those who sunburn easily), which would include the majority of Australians. It was found that clinicians play an important role in counselling patients about sun-protective behaviours, and recommended tailoring messages to the age and demographics of target groups (e.g. high-risk groups) to have maximal influence on behaviours. Several web-based melanoma risk prediction tools are now available in Australia, mainly designed for health professionals to identify patients’ risk of a new or subsequent primary melanoma and guide discussions with patients about primary prevention and early detection. Intervention studies have demonstrated that use of these melanoma risk prediction tools is feasible and acceptable to participants in primary care settings, and there is some evidence, including from Australian studies, that using these risk prediction tools to tailor primary prevention and early detection messages can improve sun-related behaviours. Some studies examined novel technologies, such as apps, to support early detection through skin examinations, including a very limited focus on the provision of preventive advice. These novel technologies are still largely in the research domain rather than recommended for routine use but provide a potential future opportunity to incorporate more primary prevention tailored advice. There are a number of online short courses available for primary healthcare professionals specifically focusing on skin cancer prevention. Most education and training programs for GPs and primary care nurses in the field of skin cancer focus on treatment and early detection, though some programs have specifically incorporated primary prevention education and training. A notable example is the Dermoscopy for Victorian General Practice Program, in which 93% of participating GPs reported that they had increased preventive information provided to high-risk patients and during skin examinations. Question 2 (related to barriers and enablers) Key enablers of performing skin cancer prevention activities in primary care settings included: • Easy access and availability of guidelines and point-of-care tools and resources • A fit with existing workflows and systems, so there is minimal disruption to flow of care • Easy-to-understand patient information • Using the waiting room for collection of risk assessment information on an electronic device such as an iPad/tablet where possible • Pairing with early detection activities • Sharing of successful programs across jurisdictions. Key barriers to performing skin cancer prevention activities in primary care settings included: • Unclear requirements and lack of confidence (self-efficacy) about prevention counselling • Limited availability of GP services especially in regional and remote areas • Competing demands, low priority, lack of time • Lack of incentives.
6
Rankin, Nicole, Deborah McGregor, Candice Donnelly, Bethany Van Dort, Richard De Abreu Lourenco, Anne Cust, and Emily Stone. Lung cancer screening using low-dose computed tomography for high risk populations: Investigating effectiveness and screening program implementation considerations: An Evidence Check rapid review brokered by the Sax Institute (www.saxinstitute.org.au) for the Cancer Institute NSW. The Sax Institute, October 2019. http://dx.doi.org/10.57022/clzt5093.
Full textAbstract:
Background Lung cancer is the number one cause of cancer death worldwide.(1) It is the fifth most commonly diagnosed cancer in Australia (12,741 cases diagnosed in 2018) and the leading cause of cancer death.(2) The number of years of potential life lost to lung cancer in Australia is estimated to be 58,450, similar to that of colorectal and breast cancer combined.(3) While tobacco control strategies are most effective for disease prevention in the general population, early detection via low dose computed tomography (LDCT) screening in high-risk populations is a viable option for detecting asymptomatic disease in current (13%) and former (24%) Australian smokers.(4) The purpose of this Evidence Check review is to identify and analyse existing and emerging evidence for LDCT lung cancer screening in high-risk individuals to guide future program and policy planning. Evidence Check questions This review aimed to address the following questions: 1. What is the evidence for the effectiveness of lung cancer screening for higher-risk individuals? 2. What is the evidence of potential harms from lung cancer screening for higher-risk individuals? 3. What are the main components of recent major lung cancer screening programs or trials? 4. What is the cost-effectiveness of lung cancer screening programs (include studies of cost–utility)? Summary of methods The authors searched the peer-reviewed literature across three databases (MEDLINE, PsycINFO and Embase) for existing systematic reviews and original studies published between 1 January 2009 and 8 August 2019. Fifteen systematic reviews (of which 8 were contemporary) and 64 original publications met the inclusion criteria set across the four questions. Key findings Question 1: What is the evidence for the effectiveness of lung cancer screening for higher-risk individuals? There is sufficient evidence from systematic reviews and meta-analyses of combined (pooled) data from screening trials (of high-risk individuals) to indicate that LDCT examination is clinically effective in reducing lung cancer mortality. In 2011, the landmark National Lung Cancer Screening Trial (NLST, a large-scale randomised controlled trial [RCT] conducted in the US) reported a 20% (95% CI 6.8% – 26.7%; P=0.004) relative reduction in mortality among long-term heavy smokers over three rounds of annual screening. High-risk eligibility criteria was defined as people aged 55–74 years with a smoking history of ≥30 pack-years (years in which a smoker has consumed 20-plus cigarettes each day) and, for former smokers, ≥30 pack-years and have quit within the past 15 years.(5) All-cause mortality was reduced by 6.7% (95% CI, 1.2% – 13.6%; P=0.02). Initial data from the second landmark RCT, the NEderlands-Leuvens Longkanker Screenings ONderzoek (known as the NELSON trial), have found an even greater reduction of 26% (95% CI, 9% – 41%) in lung cancer mortality, with full trial results yet to be published.(6, 7) Pooled analyses, including several smaller-scale European LDCT screening trials insufficiently powered in their own right, collectively demonstrate a statistically significant reduction in lung cancer mortality (RR 0.82, 95% CI 0.73–0.91).(8) Despite the reduction in all-cause mortality found in the NLST, pooled analyses of seven trials found no statistically significant difference in all-cause mortality (RR 0.95, 95% CI 0.90–1.00).(8) However, cancer-specific mortality is currently the most relevant outcome in cancer screening trials. These seven trials demonstrated a significantly greater proportion of early stage cancers in LDCT groups compared with controls (RR 2.08, 95% CI 1.43–3.03). Thus, when considering results across mortality outcomes and early stage cancers diagnosed, LDCT screening is considered to be clinically effective. Question 2: What is the evidence of potential harms from lung cancer screening for higher-risk individuals? The harms of LDCT lung cancer screening include false positive tests and the consequences of unnecessary invasive follow-up procedures for conditions that are eventually diagnosed as benign. While LDCT screening leads to an increased frequency of invasive procedures, it does not result in greater mortality soon after an invasive procedure (in trial settings when compared with the control arm).(8) Overdiagnosis, exposure to radiation, psychological distress and an impact on quality of life are other known harms. Systematic review evidence indicates the benefits of LDCT screening are likely to outweigh the harms. The potential harms are likely to be reduced as refinements are made to LDCT screening protocols through: i) the application of risk predication models (e.g. the PLCOm2012), which enable a more accurate selection of the high-risk population through the use of specific criteria (beyond age and smoking history); ii) the use of nodule management algorithms (e.g. Lung-RADS, PanCan), which assist in the diagnostic evaluation of screen-detected nodules and cancers (e.g. more precise volumetric assessment of nodules); and, iii) more judicious selection of patients for invasive procedures. Recent evidence suggests a positive LDCT result may transiently increase psychological distress but does not have long-term adverse effects on psychological distress or health-related quality of life (HRQoL). With regards to smoking cessation, there is no evidence to suggest screening participation invokes a false sense of assurance in smokers, nor a reduction in motivation to quit. The NELSON and Danish trials found no difference in smoking cessation rates between LDCT screening and control groups. Higher net cessation rates, compared with general population, suggest those who participate in screening trials may already be motivated to quit. Question 3: What are the main components of recent major lung cancer screening programs or trials? There are no systematic reviews that capture the main components of recent major lung cancer screening trials and programs. We extracted evidence from original studies and clinical guidance documents and organised this into key groups to form a concise set of components for potential implementation of a national lung cancer screening program in Australia: 1. Identifying the high-risk population: recruitment, eligibility, selection and referral 2. Educating the public, people at high risk and healthcare providers; this includes creating awareness of lung cancer, the benefits and harms of LDCT screening, and shared decision-making 3. Components necessary for health services to deliver a screening program: a. Planning phase: e.g. human resources to coordinate the program, electronic data systems that integrate medical records information and link to an established national registry b. Implementation phase: e.g. human and technological resources required to conduct LDCT examinations, interpretation of reports and communication of results to participants c. Monitoring and evaluation phase: e.g. monitoring outcomes across patients, radiological reporting, compliance with established standards and a quality assurance program 4. Data reporting and research, e.g. audit and feedback to multidisciplinary teams, reporting outcomes to enhance international research into LDCT screening 5. Incorporation of smoking cessation interventions, e.g. specific programs designed for LDCT screening or referral to existing community or hospital-based services that deliver cessation interventions. Most original studies are single-institution evaluations that contain descriptive data about the processes required to establish and implement a high-risk population-based screening program. Across all studies there is a consistent message as to the challenges and complexities of establishing LDCT screening programs to attract people at high risk who will receive the greatest benefits from participation. With regards to smoking cessation, evidence from one systematic review indicates the optimal strategy for incorporating smoking cessation interventions into a LDCT screening program is unclear. There is widespread agreement that LDCT screening attendance presents a ‘teachable moment’ for cessation advice, especially among those people who receive a positive scan result. Smoking cessation is an area of significant research investment; for instance, eight US-based clinical trials are now underway that aim to address how best to design and deliver cessation programs within large-scale LDCT screening programs.(9) Question 4: What is the cost-effectiveness of lung cancer screening programs (include studies of cost–utility)? Assessing the value or cost-effectiveness of LDCT screening involves a complex interplay of factors including data on effectiveness and costs, and institutional context. A key input is data about the effectiveness of potential and current screening programs with respect to case detection, and the likely outcomes of treating those cases sooner (in the presence of LDCT screening) as opposed to later (in the absence of LDCT screening). Evidence about the cost-effectiveness of LDCT screening programs has been summarised in two systematic reviews. We identified a further 13 studies—five modelling studies, one discrete choice experiment and seven articles—that used a variety of methods to assess cost-effectiveness. Three modelling studies indicated LDCT screening was cost-effective in the settings of the US and Europe. Two studies—one from Australia and one from New Zealand—reported LDCT screening would not be cost-effective using NLST-like protocols. We anticipate that, following the full publication of the NELSON trial, cost-effectiveness studies will likely be updated with new data that reduce uncertainty about factors that influence modelling outcomes, including the findings of indeterminate nodules. Gaps in the evidence There is a large and accessible body of evidence as to the effectiveness (Q1) and harms (Q2) of LDCT screening for lung cancer. Nevertheless, there are significant gaps in the evidence about the program components that are required to implement an effective LDCT screening program (Q3). Questions about LDCT screening acceptability and feasibility were not explicitly included in the scope. However, as the evidence is based primarily on US programs and UK pilot studies, the relevance to the local setting requires careful consideration. The Queensland Lung Cancer Screening Study provides feasibility data about clinical aspects of LDCT screening but little about program design. The International Lung Screening Trial is still in the recruitment phase and findings are not yet available for inclusion in this Evidence Check. The Australian Population Based Screening Framework was developed to “inform decision-makers on the key issues to be considered when assessing potential screening programs in Australia”.(10) As the Framework is specific to population-based, rather than high-risk, screening programs, there is a lack of clarity about transferability of criteria. However, the Framework criteria do stipulate that a screening program must be acceptable to “important subgroups such as target participants who are from culturally and linguistically diverse backgrounds, Aboriginal and Torres Strait Islander people, people from disadvantaged groups and people with a disability”.(10) An extensive search of the literature highlighted that there is very little information about the acceptability of LDCT screening to these population groups in Australia. Yet they are part of the high-risk population.(10) There are also considerable gaps in the evidence about the cost-effectiveness of LDCT screening in different settings, including Australia. The evidence base in this area is rapidly evolving and is likely to include new data from the NELSON trial and incorporate data about the costs of targeted- and immuno-therapies as these treatments become more widely available in Australia.